デフォルト表紙
市場調査レポート
商品コード
1514212

バイオエンジニアリング蛋白質医薬品の世界市場

Bioengineered Protein Drugs

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
バイオエンジニアリング蛋白質医薬品の世界市場
出版日: 2024年07月17日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

バイオエンジニアリングタンパク質医薬品の世界市場は2030年までに3,299億米ドルに到達

2023年に2,455億米ドルと推定されるバイオエンジニアリングタンパク質医薬品の世界市場は、2023～2030年にかけてCAGR 4.3%で成長し、2030年には3,299億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである治療用タンパク質は、CAGR 3.9%を記録し、分析期間終了時には1,292億米ドルに達すると予想されます。モノクローナル抗体セグメントの成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は662億米ドルと推定、中国はCAGR 7.2%で成長予測

米国のバイオエンジニアリングタンパク質医薬品市場は2023年に662億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに694億米ドルの市場規模に達すると予測され、分析期間2023～2030年のCAGRは7.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と4.9%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

バイオエンジニアリングタンパク質医薬品-主要動向と促進要因

バイオ医薬品としても知られるバイオエンジニアリングタンパク質医薬品は、医療セグメントに革命をもたらし、幅広い疾患に対して的を絞った効果的な治療を提供しています。これらの医薬品は、高度な遺伝子工学技術を用いて開発され、人体に自然に存在するタンパク質と同一のタンパク質を生産することができます。これらのタンパク質は、特定の生物学的経路と相互作用するように設計することができ、疾病メカニズムへの正確な介入を可能にします。例えば、がん治療に使われるモノクローナル抗体や、糖尿病管理のためのインスリンアナログなどです。組換えDNA技術と厳密な精製工程を伴う開発の複雑さにより、高い特異性と有効性が保証され、従来の低分子医薬品とは一線を画しています。その結果、バイオエンジニアリングタンパク質医薬品は、関節リウマチ、多発性硬化症、各種がんなどの慢性疾患の治療の要となっています。

バイオエンジニアリングタンパク質医薬品の規制状況は、その生物学的起源と複雑性から、安全性と有効性を確保する必要性を反映し、厳しいものとなっています。承認プロセスには通常、副作用や長期的転帰をモニターするための大規模な臨床試験と市販後調査が含まれます。CRISPRやその他の遺伝子編集ツールなどのバイオテクノロジーの革新は、これらの医薬品の開発をさらに加速し、より正確な改変を可能にし、開発期間を短縮する可能性があります。さらに、バイオプロセスや製造技術の進歩により、生物工学的に改変されたタンパク質を生産するスケーラビリティと費用対効果が向上しています。

バイオエンジニアリングタンパク質医薬品市場の成長は、技術の進歩、慢性疾患の有病率の増加、個別化医療の受容と需要の高まりなど、いくつかの要因によってもたらされます。技術革新によって医薬品開発プロセスが合理化され、コストと市場開拓期間が短縮される一方、バイオ医薬品企業はこうした進歩を活用して、より強力で的を絞った治療を開発しています。また、がん、糖尿病、自己免疫疾患などの慢性疾患の罹患率の上昇も、こうした先端治療への需要を高めています。さらに、消費者の行動動向は、個別化医療への強い嗜好を示しており、バイオエンジニアリングタンパク質は、個人の遺伝子プロファイルに合わせることができるため、これを実現する上で独自の地位を占めています。加えて、多くの地域で有利な規制政策と医療資金の増加が、市場の急速な拡大を支えています。官民両部門による研究開発への投資も極めて重要で、継続的な技術革新と次世代バイオ医薬品の採用を後押ししています。

調査対象企業の例（注目の56社）

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG

目次

第1章 調査手法

第2章 エグゼクティブ概要

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の展望

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6377

Global Bioengineered Protein Drugs Market to Reach US$329.9 Billion by 2030

The global market for Bioengineered Protein Drugs estimated at US$245.5 Billion in the year 2023, is expected to reach US$329.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2023-2030. Therapeutic Proteins, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$129.2 Billion by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$66.2 Billion While China is Forecast to Grow at 7.2% CAGR

The Bioengineered Protein Drugs market in the U.S. is estimated at US$66.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$69.4 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Bioengineered Protein Drugs - Key Trends and Drivers

Bioengineered protein drugs, also known as biopharmaceuticals, have revolutionized the field of medicine, offering targeted and effective treatments for a wide range of diseases. These drugs are developed using advanced genetic engineering techniques that allow for the production of proteins identical to those naturally occurring in the human body. These proteins can be designed to interact with specific biological pathways, enabling precise intervention in disease mechanisms. Examples include monoclonal antibodies, used in cancer therapy, and insulin analogs for diabetes management. The complexity of their development, involving recombinant DNA technology and rigorous purification processes, ensures high specificity and efficacy, distinguishing them from traditional small-molecule drugs. As a result, bioengineered protein drugs have become a cornerstone in treating chronic conditions such as rheumatoid arthritis, multiple sclerosis, and various types of cancers.

The regulatory landscape for bioengineered protein drugs is stringent, reflecting the need for ensuring safety and efficacy given their biological origin and complexity. The approval process typically involves extensive clinical trials and post-marketing surveillance to monitor adverse effects and long-term outcomes. Innovations in biotechnology, such as CRISPR and other gene-editing tools, have further accelerated the development of these drugs, enabling more precise modifications and potentially reducing development times. Moreover, advancements in bioprocessing and manufacturing techniques have improved the scalability and cost-effectiveness of producing bioengineered proteins. As these technologies evolve, the pipeline of bioengineered protein drugs continues to expand, addressing unmet medical needs and offering new hope for patients with previously untreatable conditions.

The growth in the bioengineered protein drugs market is driven by several factors, including technological advancements, increased prevalence of chronic diseases, and growing acceptance and demand for personalized medicine. Technological innovations have streamlined the drug development process, reducing costs and time-to-market, while biopharmaceutical companies are leveraging these advancements to develop more potent and targeted therapies. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders has also heightened the demand for these advanced treatments. Furthermore, consumer behavior trends indicate a strong preference for personalized medicine, which bioengineered proteins are uniquely positioned to deliver due to their ability to be tailored to individual genetic profiles. Additionally, favorable regulatory policies and increased healthcare funding in many regions are supporting the rapid market expansion. Investment in research and development by both private and public sectors is also pivotal, driving continuous innovation and the introduction of next-generation biopharmaceuticals.

Select Competitors (Total 56 Featured) -

  • Abbott India Ltd.
  • Amgen, Inc.
  • Bayer AG
  • Biocon Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Panacea Biotec Ltd.
  • ProBioGen AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Bioengineered Protein Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Genetic Engineering Propel Growth in Bioengineered Protein Drugs Market
    • Increasing Prevalence of Chronic Diseases Expands Addressable Market Opportunity
    • Personalized Medicine Trends Strengthen Business Case for Bioengineered Proteins
    • Innovations in Bioprocessing Technologies Drive Cost-Efficiency and Scalability
    • Rising Consumer Demand for Targeted Therapies Generates Opportunities
    • Adoption of CRISPR and Gene-Editing Tools Accelerates Development Timelines
    • Healthcare Funding Increases Propel Market Adoption
    • Enhanced Purification Techniques Improve Drug Safety and Efficacy
    • Advanced Manufacturing Technologies Enhance Production Capabilities
    • Post-Marketing Surveillance Strengthens Confidence in Bioengineered Protein Drugs
    • Technological Synergies with Digital Health Tools Enhance Treatment Outcomes
    • Novel Drug Delivery Systems Expand Therapeutic Applications
    • Data Analytics and AI Integration Improve Drug Development Efficiency
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bioengineered Protein Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Academics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • JAPAN
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • CHINA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • EUROPE
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • FRANCE
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • GERMANY
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • INDIA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Bioengineered Protein Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Bioengineered Protein Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030
  • AFRICA
    • Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2014, 2024 & 2030

IV. COMPETITION